TY - JOUR
T1 - Association of lipid profile biomarkers with breast cancer by molecular subtype
T2 - analysis of the MEND study
AU - Gupta, Anjali
AU - Saraiya, Veeral
AU - Deveaux, April
AU - Oyekunle, Taofik
AU - Jackson, Klarissa D.
AU - Salako, Omolola
AU - Daramola, Adetola
AU - Hall, Allison
AU - Alatise, Olusegun
AU - Ogun, Gabriel
AU - Adeniyi, Adewale
AU - Ayandipo, Omobolaji
AU - Olajide, Thomas
AU - Olasehinde, Olalekan
AU - Arowolo, Olukayode
AU - Adisa, Adewale
AU - Afuwape, Oludolapo
AU - Olusanya, Aralola
AU - Adegoke, Aderemi
AU - Tollefsbol, Trygve O.
AU - Arnett, Donna
AU - Muehlbauer, Michael J.
AU - Newgard, Christopher B.
AU - Ajayi, Samuel
AU - Raji, Yemi
AU - Olanrewaju, Timothy
AU - Osafo, Charlotte
AU - Ulasi, Ifeoma
AU - Asinobi, Adanze
AU - Winkler, Cheryl A.
AU - Burke, David
AU - Arogundade, Fatiu
AU - Ekem, Ivy
AU - Plange-Rhule, Jacob
AU - Mamven, Manmak
AU - Mate-kole, Michael
AU - Amodu, Olukemi
AU - Cooper, Richard
AU - Antwi, Sampson
AU - Adeyemo, Adebowale
AU - Ilori, Titilayo
AU - Adabayeri, Victoria
AU - Nyarko, Alexander
AU - Ghansah, Anita
AU - Amos-Abanyie, Ernestine Kubi
AU - Akyaw, Priscilla Abena
AU - Kimmel, Paul L.
AU - Salako, Babatunde L.
AU - Parekh, Rulan S.
AU - Tayo, Bamidele
N1 - Funding Information:
We acknowledge the role of the H3Africa Consortium in making this research possible though the sharing of data. The National Institutes of Health (USA) and Wellcome Trust (UK) have provided the core funding for the H3Africa Consortium. We thank the many MEND investigators who contributed substantially to the inception and design of the study, and the patients and families who participated in the MEND study for their vital contribution in advancing the science of cancer in Nigeria and globally. We acknowledge the important contribution of the MEND research nurses: Cordelia Ibeneme, Peju Olabanji, Rebecca Israel, Esther Akinwale, Deborah Awodeyi, and Shukurat Oduola.
Funding Information:
This research was specifically funded by National Institutes of Health, National Cancer Institute, Fogarty International Center (K01TW010271, T.A.), and National Institutes of Health (NIH 1P30DK124723-01). The views expressed in this paper do not represent the views of the National Institutes of Health, H3Africa Consortium or their funders.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - There is conflicting evidence on the role of lipid biomarkers in breast cancer (BC), and no study to our knowledge has examined this association among African women. We estimated odds ratios (ORs) and 95% confidence intervals (95% CI) for the association of lipid biomarkers—total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides—with odds of BC overall and by subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC) for 296 newly diagnosed BC cases and 116 healthy controls in Nigeria. Each unit standard deviation (SD) increase in triglycerides was associated with 39% increased odds of BC in fully adjusted models (aOR: 1.39; 95% CI: 1.03, 1.86). Among post-menopausal women, higher total cholesterol (aOR: 1.65; 95% CI: 1.06, 2.57), LDL cholesterol (aOR: 1.59; 95% CI: 1.04, 2.41), and triglycerides (aOR: 1.91; 95% CI: 1.21, 3.01) were associated with increased odds of BC. Additionally, each unit SD increase in LDL was associated with 64% increased odds of Luminal B BC (aOR 1.64; 95% CI: 1.06, 2.55). Clinically low HDL was associated with 2.7 times increased odds of TNBC (aOR 2.67; 95% CI: 1.10, 6.49). Among post-menopausal women, higher LDL cholesterol and triglycerides were significantly associated with increased odds of Luminal B BC and HER2 BC, respectively. In conclusion, low HDL and high LDL are associated with increased odds of TN and Luminal B BC, respectively, among African women. Future prospective studies can definitively characterize this association and inform clinical approaches targeting HDL as a BC prevention strategy.
AB - There is conflicting evidence on the role of lipid biomarkers in breast cancer (BC), and no study to our knowledge has examined this association among African women. We estimated odds ratios (ORs) and 95% confidence intervals (95% CI) for the association of lipid biomarkers—total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides—with odds of BC overall and by subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC) for 296 newly diagnosed BC cases and 116 healthy controls in Nigeria. Each unit standard deviation (SD) increase in triglycerides was associated with 39% increased odds of BC in fully adjusted models (aOR: 1.39; 95% CI: 1.03, 1.86). Among post-menopausal women, higher total cholesterol (aOR: 1.65; 95% CI: 1.06, 2.57), LDL cholesterol (aOR: 1.59; 95% CI: 1.04, 2.41), and triglycerides (aOR: 1.91; 95% CI: 1.21, 3.01) were associated with increased odds of BC. Additionally, each unit SD increase in LDL was associated with 64% increased odds of Luminal B BC (aOR 1.64; 95% CI: 1.06, 2.55). Clinically low HDL was associated with 2.7 times increased odds of TNBC (aOR 2.67; 95% CI: 1.10, 6.49). Among post-menopausal women, higher LDL cholesterol and triglycerides were significantly associated with increased odds of Luminal B BC and HER2 BC, respectively. In conclusion, low HDL and high LDL are associated with increased odds of TN and Luminal B BC, respectively, among African women. Future prospective studies can definitively characterize this association and inform clinical approaches targeting HDL as a BC prevention strategy.
UR - http://www.scopus.com/inward/record.url?scp=85132680034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132680034&partnerID=8YFLogxK
U2 - 10.1038/s41598-022-13740-x
DO - 10.1038/s41598-022-13740-x
M3 - Article
C2 - 35739205
AN - SCOPUS:85132680034
SN - 2045-2322
VL - 12
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 10631
ER -
